Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 49.


Zhu, Jingjing, Bing, Chen and Wilding, John PH ORCID: 0000-0003-2839-8404
(2019) 1,25(OH)(2)D-3 attenuates IL-6 and IL-1-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-B signaling pathways. DIABETOLOGY & METABOLIC SYNDROME, 11.


Zhu, Jingjing and Wilding, John PH ORCID: 0000-0003-2839-8404
(2020) The 1α,25(OH)2D3 Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-κB and MAPK Signaling. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13. 1715 - 1724.


le Roux, Carel W, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Lau, David CW, Van Gaal, Luc, Ortiz, Rafael Violante, Wilding, John PH ORCID: 0000-0003-2839-8404, Skjoth, Trine V, Manning, Linda Shapiro
et al (show 2 more authors) (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. LANCET, 389 (10077). 1399 - 1409.


Williams, Scott M, Eleftheriadou, Aikaterini, Alam, Uazman ORCID: 0000-0002-3190-1122, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Wilding, John PH ORCID: 0000-0003-2839-8404
(2019) Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review. DIABETES THERAPY, 10 (6). 1995 - 2021.


Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L
et al (show 8 more authors) (2021) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23 (1). 29 - 38.


Wilding, John PH ORCID: 0000-0003-2839-8404 and Jacob, Stephan
(2020) Cardiovascular outcome trials in obesity: A review. Obesity reviews : an official journal of the International Association for the Study of Obesity.


Cahn, Avivit ORCID: 0000-0003-0209-4453, Raz, Itamar ORCID: 0000-0002-1040-6229, Leiter, Lawrence A ORCID: 0000-0002-5702-7584, Mosenzon, Ofri ORCID: 0000-0002-7830-9994, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Bhatt, Deepak L, McGuire, Darren K ORCID: 0000-0002-6412-7989
et al (show 5 more authors) (2021) Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes care.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit
et al (show 5 more authors) (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation.


Johansson, Lars, Hockings, Paul, Frias, Juan P, Suchower, Lisa, Maaske, Jill, Iqbal, Nayyar and Wilding, John PH ORCID: 0000-0003-2839-8404
(2020) DAPAGLIFLOZIN PLUS SAXAGLIPTIN ADD-ON TO METFORMIN MAINTAINS REDUCED LIVER FAT AND ADIPOSE TISSUE VOLUMES IN PATIENTS WITH TYPE 2 DIABETES OVER 122 WEEKS. .


Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 5 more authors) (2018) DECLARE-TIMI 58: Participants' baseline characteristics. DIABETES OBESITY & METABOLISM, 20 (5). 1102 - 1110.


Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 8 more authors) (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). 734 - 747.


Johansson, Lars, Hockings, Paul D, Johnsson, Eva, Dronamraju, Nalina, Maaske, Jill, Garcia-Sanchez, Ricardo and Wilding, John PH ORCID: 0000-0003-2839-8404
(2020) Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes. DIABETES OBESITY & METABOLISM, 22 (7). 1094 - 1101.


Fatani, Sameer, Pickavance, Lucy C, Sadler, Claire J, Harrold, Joanne A ORCID: 0000-0002-0899-4586, Cassidy, Roslyn, Wilding, John PH ORCID: 0000-0003-2839-8404 and Naderali, Ebrahim K
(2007) Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study. NUTRITION & METABOLISM, 4.


Skyler, Jay S, Bakris, George L, Bonifacio, Ezio, Darsow, Tamara, Eckel, Robert H, Groop, Leif, Groop, Per-Henrik, Handelsman, Yehuda, Insel, Richard A, Mathieu, Chantal
et al (show 7 more authors) (2017) Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. DIABETES, 66 (2). 241 - 255.


Fujioka, Ken, O'Neil, Patrick M, Davies, Melanie, Greenway, Frank, Lau, David CW, Claudius, Birgitte, Skjoth, Trine Vang, Jensen, Christine Bjorn and Wilding, John PH ORCID: 0000-0003-2839-8404
(2016) Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. OBESITY, 24 (11). 2278 - 2288.


Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 13 more authors) (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139 (22). 2528 - 2536.


Budoff, Matthew J and Wilding, John PH ORCID: 0000-0003-2839-8404
(2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 71 (5).


Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P
et al (show 11 more authors) (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). 606 - 617.


Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K
et al (show 7 more authors) (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43 (2). 468 - 475.


O'Neil, Patrick M, Birkenfeld, Andreas L, McGowan, Barbara, Mosenzon, Ofri, Pedersen, Sue D, Wharton, Sean, Carson, Charlotte Giwercman, Jepsen, Cecilie Heerdegen, Kabisch, Maria and Wilding, John PH ORCID: 0000-0003-2839-8404
(2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. LANCET, 392 (10148). 637 - 649.


Wilding, John PH ORCID: 0000-0003-2839-8404
(2020) Endocrine testing in obesity. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 182 (4). C13 - C15.


Wharton, Sean, Astrup, Arne, Endahl, Lars, Lean, Michael EJ, Satylganova, Altynai, Skovgaard, Dorthe, Wadden, Thomas A and Wilding, John PH ORCID: 0000-0003-2839-8404
(2021) Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. INTERNATIONAL JOURNAL OF OBESITY.


Thondam, Sravan K, Daousi, Christina, Wilding, John PH ORCID: 0000-0003-2839-8404, Holst, Jens J, Ameen, Gulizar I ORCID: 0000-0001-8895-3145, Yang, Chenjing, Whitmore, Catherine, Mora, Silvia and Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822
(2017) Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 312 (3). E224 - E233.


Gorst, Sarah L ORCID: 0000-0002-7818-9646, Young, Bridget ORCID: 0000-0001-6041-9901, Williamson, Paula R ORCID: 0000-0001-9802-6636, Wilding, John PH ORCID: 0000-0003-2839-8404 and Harman, Nicola ORCID: 0000-0001-6958-6466
(2019) Incorporating Patients' Perspectives into the Initial Stages of Core Outcome Set Development: A Rapid Review of Qualitative Studies of Type 2 Diabetes. BMJ Open Diabetes Research and Care.


Bray, George A, Fruhbeck, Gema, Ryan, Donna H and Wilding, John PH ORCID: 0000-0003-2839-8404
(2016) Management of obesity. LANCET, 387 (10031). 1947 - 1956.


Wilding, John PH ORCID: 0000-0003-2839-8404
(2018) Medication use for the treatment of diabetes in obese individuals. DIABETOLOGIA, 61 (2). 265 - 272.


Sprung, Victoria S ORCID: 0000-0002-2666-4986, Davies, Kelly A Bowden, Norman, Juliette A, Thompson, Andrew ORCID: 0000-0002-7087-9415, Mitchell, Katie L, Wilding, John PH ORCID: 0000-0003-2839-8404, Kemp, Graham J ORCID: 0000-0002-8324-9666 and Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822
(2020) Metabolic syndrome is associated with reduced flow mediated dilation independent of obesity status. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 183 (2). 211 - 220.


O'Neil, Patrick M, Aroda, Vanita R, Astrup, Arne, Kushner, Robert, Lau, David CW, Wadden, Thomas A, Brett, Jason, Cancino, Ana-Paula, Wilding, John PH ORCID: 0000-0003-2839-8404 and Adiposity, Satiety Clinical
(2017) Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. DIABETES OBESITY & METABOLISM, 19 (11). 1529 - 1536.


Psarou, Aikaterini, Cooper, Helen and Wilding, John PH ORCID: 0000-0003-2839-8404
(2018) Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. DIABETES THERAPY, 9 (5). 1791 - 1810.


Bowden Davies, Kelly A, Sprung, Victoria S ORCID: 0000-0002-2666-4986, Norman, Juliette A, Thompson, Andrew ORCID: 0000-0002-7087-9415, Mitchell, Katie L, Harrold, Jo A ORCID: 0000-0002-0899-4586, Finlayson, Graham, Gibbons, Catherine, Wilding, John PH ORCID: 0000-0003-2839-8404, Kemp, Graham J ORCID: 0000-0002-8324-9666
et al (show 2 more authors) (2019) Physical Activity and Sedentary Time: Association with Metabolic Health and Liver Fat. Medicine and science in sports and exercise, 51 (6). 1169 - 1177.


Wilding, John PH ORCID: 0000-0003-2839-8404, Rajeev, Surya Panicker and DeFronzo, Ralph A
(2016) Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm. DIABETES CARE, 39. S154 - S164.


Maria Agra, Rosa, Al-Daghri, Nasser M, Badimon, Lina, Bodi, Vicente, Carbone, Federico, Chen, Mao, Cubedo, Judit, Dullaart, Robin PF, Eiras, Sonia, Garcia-Monzon, Carmelo
et al (show 37 more authors) (2016) Research update for articles published in EJCI in 2014. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 46 (10). 880 - 894.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM
et al (show 5 more authors) (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). 31 - 39.


Kashiwagi, Atsunori, Shestakova, Marina V, Ito, Yuichiro, Noguchi, Masahiro, Wilpshaar, Wim, Yoshida, Satoshi and Wilding, John PH ORCID: 0000-0003-2839-8404
(2019) Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. DIABETES THERAPY, 10 (6). 2201 - 2217.


Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K
et al (show 9 more authors) (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). 1357 - 1368.


Kushner, Robert F, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A, Wharton, Sean
et al (show 2 more authors) (2020) Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. OBESITY, 28 (6). 1050 - 1061.


Ahren, Bo, Atkin, Stephen L, Charpentier, Guillaume, Warren, Mark L, Wilding, John PH ORCID: 0000-0003-2839-8404, Birch, Sune, Holst, Anders Gaarsdal and Leiter, Lawrence A
(2018) Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. DIABETES OBESITY & METABOLISM, 20 (9). 2210 - 2219.


Bowden Davies, Kelly A, Sprung, Victoria S ORCID: 0000-0002-2666-4986, Norman, Juliette A, Thompson, Andrew ORCID: 0000-0002-7087-9415, Mitchell, Katie L, Halford, Jason CG, Harrold, Jo A ORCID: 0000-0002-0899-4586, Wilding, John PH ORCID: 0000-0003-2839-8404, Kemp, Graham J ORCID: 0000-0002-8324-9666 and Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822
(2018) Short-term decreased physical activity with increased sedentary behaviour causes metabolic derangements and altered body composition: effects in individuals with and without a first-degree relative with type 2 diabetes. Diabetologia, 61 (6). 1282 - 1294.


Wilding, John PH ORCID: 0000-0003-2839-8404, Mooney, Vicki and Pile, Richard
(2019) Should obesity be recognised as a disease? BMJ-BRITISH MEDICAL JOURNAL, 366.


Zhu, Jingjing, Bing, Chen and Wilding, John PH ORCID: 0000-0003-2839-8404
(2018) Vitamin D receptor ligands attenuate the inflammatory profile of IL-1 beta-stimulated human white preadipocytes via modulating the NF-kappa B and unfolded protein response pathways. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 503 (2). 1049 - 1056.


Bray, George A, Fruhbeck, Gema, Ryan, Donna H and Wilding, John PH ORCID: 0000-0003-2839-8404
(2016) Weighing up dietary patterns Reply. LANCET, 388 (10046). 759 - 760.


Brown, Emily, Wilding, John PH ORCID: 0000-0003-2839-8404, Barber, Thomas M, Alam, Uazman ORCID: 0000-0002-3190-1122 and Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822
(2019) Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. OBESITY REVIEWS, 20 (6). 816 - 828.


Shillito, James A, Lea, James, Tierney, Stephanie, Cleator, Jacqueline, Tai, Sara and Wilding, John PH ORCID: 0000-0003-2839-8404
(2018) Why I eat at night: A qualitative exploration of the development, maintenance and consequences of Night Eating Syndrome. APPETITE, 125. 270 - 277.


McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit
et al (show 1 more authors) (2021) The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM.


Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 6 more authors) (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. AMERICAN HEART JOURNAL, 200. 83 - 89.


Thondam, Sravan K, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Wilding, John PH ORCID: 0000-0003-2839-8404
(2019) The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides. 170208 - 170208.


Shestakova, Marina V, Wilding, John PH ORCID: 0000-0003-2839-8404, Wilpshaar, Wim, Tretter, Reiner, Orlova, Valeria L and Verbovoy, Andrey F
(2018) A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. DIABETES RESEARCH AND CLINICAL PRACTICE, 146. 240 - 250.


Eleftheriadou, Aikaterini, Williams, Scott, Nevitt, Sarah ORCID: 0000-0001-9988-2709, Brown, Emily, Roylance, Rebecca, Wilding, John PH ORCID: 0000-0003-2839-8404, Cuthbertson, Daniel J ORCID: 0000-0002-6128-0822 and Alam, Uazman ORCID: 0000-0002-3190-1122
(2021) The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. DIABETOLOGIA, 64 (2). 288 - 303.


Boyle, Luke D and Wilding, John PH ORCID: 0000-0003-2839-8404
(2014) A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes. EXPERT OPINION ON DRUG SAFETY, 13 (11). 1535 - 1544.

This list was generated on Mon Apr 12 01:33:50 2021 BST.